Robert Bruce's top dividend stocks (August 2025) include Pfizer Inc. (PFE), a leading global pharmaceutical and biotechnology corporation.

Robert Bruce is a notable figure in the investment community, known for his work as an investment manager. His investment focus often centers on identifying value opportunities within various market sectors, guiding his portfolio decisions with a long-term perspective.

Pfizer Inc. (PFE)

Pfizer is a global pharmaceutical giant, well-known for discovering, developing, manufacturing, and marketing medicines and vaccines for humans. The company's extensive portfolio covers areas like internal medicine, oncology, inflammation, rare diseases, and vaccines, serving patients worldwide. In Robert Bruce's portfolio, this position is valued at $6.33 million, offering an impressive dividend yield of approximately 8.59%. Shareholders have seen a trailing twelve-month dividend rate of $2.13. Analysts have set a price target of $24.0 for the stock, while its discounted cash flow value stands at $64.3.
Here's an overview of Robert Bruce's trades in Pfizer Inc.:

Organon & Co. (OGN)

Organon & Co. is a global healthcare company with a focus on women's health, biosimilars, and established brands. It provides a wide range of therapeutic products, including reproductive medicine, contraception, and chronic disease treatments, reaching patients in over 140 markets. The current portfolio position for Organon & Co. in Robert Bruce's holdings is worth $302.64 thousand, and the company yields an attractive dividend of around 8.42%. Its TTM dividend rate is $0.86, and the analyst consensus price target for Organon is $14.0. The discounted cash flow for Organon is calculated at $28.3.
Here's an overview of Robert Bruce's trades in Organon & Co.:

Chemours Company (CC)

The Chemours Company is a global chemical company that provides performance chemicals, including titanium technologies, fluoroproducts, and chemical solutions. Their products are essential across various industries, from refrigerants and industrial polymers to coatings and specialized materials. Robert Bruce maintains a position in Chemours Company valued at $2.4 million, which currently boasts a dividend yield of about 5.91%. The trailing twelve-month dividend rate for Chemours is $0.84, with analysts suggesting a price target of $16.0. The discounted cash flow value is -$3.71.
Here's an overview of Robert Bruce's trades in Chemours Company:

Avista Corp. (AVA)

Avista Corp. is an energy company involved in the generation, transmission, and distribution of electricity and natural gas. Serving customers across parts of Washington, Idaho, and Oregon, the company primarily operates in the regulated utility sector, providing essential services to communities. The current value of this utility stock in Robert Bruce's portfolio is $7.52 million. Avista Corp. offers a robust dividend yield of approximately 5.19%, with a trailing twelve-month dividend rate of $1.93.
Here's an overview of Robert Bruce's trades in Avista Corp.:

Viatris Inc (VTRS)

Viatris Inc. is a global healthcare company that provides access to medicines, advancing sustainable operations, and developing innovative solutions. Their portfolio includes a wide range of products across key therapeutic areas, including cardiovascular, pain management, central nervous system, and anti-infectives. Robert Bruce's current holding in Viatris Inc is valued at $509.07 thousand. The company offers investors a dividend yield of around 5.10%, and its trailing twelve-month dividend rate stands at $0.48. Additionally, the discounted cash flow analysis for Viatris suggests a value of $34.51.
Here's an overview of Robert Bruce's trades in Viatris Inc: